Business
BioVie to Host Live Investor Webinar and Q&A on Oct. 8
CARSON CITY, Nev., Sept. 26, 2025 (GLOBE NEWSWIRE) -- BioVie Inc. (NASDAQ: BIVI) (“BioVie” or the “Company”), a clinical-stage company developing innovative drug therapies for neurological and neurodegenerative diseases, will host an investor webinar at 4:15 p.m. ET on Wednesday, Oct. 8, 2025. The exclusive event, hosted by RedChip Companies, will feature Cuong Do, president and CEO of BioVie, who will discuss bezisterim (NE3107), the company’s first-in-class, orally available small molecule tha
About this update from Biovie Inc.
[{"type":"image","alt":"BioVie, Inc.","displaySize":"","headline":null,"caption":"BioVie, Inc.","className":"","disableSlideshowImg":false,"size":{"original":{"width":300,"height":79,"url":"https://media.zenfs.com/en/globenewswire.com/3ea77a11e9aebc3c51a1eb5247357a7a"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/74wuLVBY92R9d2c1AJ.QhA--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTExMTtjZj13ZWJw/https://media.zenfs.com/en/globenewswire.com/3ea77a11e9aebc3c51a1eb5247357a7a","width":300,"height":79}},"lazy":false},{"type":"text","content":"CARSON CITY, Nev., Sept. 26, 2025 (GLOBE NEWSWIRE) -- BioVie Inc. (NASDAQ: BIVI) (“BioVie” or the “Company”), a clinical-stage company developing innovative drug therapies for neurological and neurodegenerative diseases, will host an investor webinar at 4:15 p.m. ET on Wednesday, Oct. 8, 2025.","length":294,"tagName":"p"},{"type":"text","content":"The exclusive event, hosted by RedChip Companies, will feature Cuong Do, president and CEO of BioVie, who will discuss bezisterim (NE3107), the company’s first-in-class, orally available small molecule that targets inflammation and insulin resistance, two key drivers of Alzheimer’s, Parkinson’s, and long COVID. Clinical studies have shown encouraging signals of improved cognition, motor function and reduced neuroinflammation. Do will also outline progress with BIV201, BioVie’s late-stage orphan drug candidate for refractory ascites, a life-threatening complication of liver cirrhosis that currently has no FDA-approved therapies.","length":635,"tagName":"p"},{"type":"text","content":"With several late-stage clinical programs underway and supportive safety data, BioVie is advancing toward key milestones and evaluating potential partnerships in markets with significant commercial potential.","length":208,"tagName":"p"},{"type":"text","content":"A live Q&A session with management will follow the presentation.","length":68,"tagName":"p"},{"type":"text","content":"To register for the free webinar, please visit: https://www.redchip.com/webinar/BIVI/87879092882","length":96,"tagName":"p"},{"type":"text","content":"Questions can be pre-submitted to [email protected] or online during the live event.","length":83,"tagName":"p"},{"type":"text","content":"About BioVie, Inc.","length":18,"tagName":"p"},{"type":"text","content":"BioVie Inc. (NASDAQ: BIVI) is a clinical-stage company developing ...